Who is sponsoring NCT04047550?

NCT04047550 is sponsored by Duke University.

What drugs are being tested in NCT04047550?

Interventions in NCT04047550: Ventilatory chemosensitivity.

What condition does NCT04047550 study?

NCT04047550 studies Ventilatory Depression, Opioid Intoxication, Opioid Toxicity.

Is NCT04047550 still recruiting?

NCT04047550 is currently completed. Last updated 27 August 2020.

Last reviewed 2020-08-27 · How we verify

NCT04047550

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Respiratory Control and Narcotic Effects

Completed Last updated 27 August 2020

What this trial tests

trial testing Ventilatory chemosensitivity in Ventilatory Depression in 10 participants. Completed in 9 February 2019.

Timeline

8 March 2018

Primary endpoint
9 February 2019

9 February 2019

Quick facts

Lead sponsor	Duke University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	10
Start date	8 March 2018
Primary completion	9 February 2019
Estimated completion	9 February 2019
Sites	1 location across United States

Drugs / interventions tested

Ventilatory chemosensitivity

Conditions studied

Ventilatory Depression — all drugs for Ventilatory Depression →
Opioid Intoxication — all drugs for Opioid Intoxication →
Opioid Toxicity — all drugs for Opioid Toxicity →

Sponsor

Duke University

Who can join

18 and older, any sex, with Ventilatory Depression or Opioid Intoxication. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to provide data that will assess the role of ventilatory chemosensitivity (respiratory drive) in determining postoperative respiratory depression due to opioids. In a group of patients requiring surgery and admission to hospital, before surgery, ventilatory chemosensitivity will be assessed in the presence or absence of an infusion of remifentanil. Parameters will be correlated with ventilatory depression events after surgery. A secondary aim is to determine whether respiratory depression is more likely during specific phases of sleep.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Duke University trials

Trials by the same sponsor.

NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04047550 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Duke University
Last refreshed: 27 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04047550.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing